Akt Is Essential for Insulin Modulation of Amphetamine-Induced Human Dopamine Transporter Cell-Surface Redistribution

B. G. Garcia, Y. Wei, J. A. Moron, R. Z. Lin, J. A. Javitch, and A. Galli

Department of Molecular Physiology and Biophysics, Center for Molecular Neuroscience, Vanderbilt University, Nashville, Tennessee (B.G.G., Y.W., J.A.M., A.G.); Departments of Medicine and Physiology, State University of New York at Stony Brook, Stony Brook, New York (R.Z.L.); and Departments of Psychiatry and Pharmacology, Center for Molecular Recognition, College of Physicians and Surgeons, Columbia University, New York, New York (J.A.J.)

Received November 10, 2004; accepted March 28, 2005

ABSTRACT

Uptake by the dopamine transporter (DAT) is the primary pathway for the clearance of extracellular dopamine (DA) and consequently for regulating the magnitude and duration of dopaminergic signaling. Amphetamine (AMPH) has been shown to decrease simultaneously DAT cell-surface expression and [3H]DA uptake. We have shown that insulin and its subsequent signaling through the phosphatidylinositol 3-kinase (PI3K)-dependent pathway oppose this effect of AMPH by promoting increased cell-surface expression. Here, we used human embryonic kidney 293 cells stably expressing the human DAT (hDAT cells) to investigate the downstream cellular components important for this effect of insulin. Akt is a protein kinase effector immediately downstream of PI3K. Both overexpression of a dominant-negative mutant of Akt (K179R) and the addition of 1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine HCl (ML9), a pharmacological inhibitor of Akt, decreased cell-surface expression of DAT, suggesting a role of basal Akt signaling in the homoeostasis of DAT. Moreover, expression of a constitutively active Akt mutant reduced the ability of AMPH to decrease hDAT cell-surface expression as well as [3H]DA uptake. In contrast, overexpression of K179R blocked the ability of insulin to oppose AMPH-induced reduction of hDAT cell-surface expression and [3H]DA uptake, as did ML9. Our data demonstrate that hDAT cell-surface expression is regulated by the hormonal modulation of AMPH-induced hDAT trafficking and in the regulation of basal hDAT cell-surface expression.

Dopaminergic neurotransmission is determined by extracellular DA levels, which in turn are regulated principally by DAT-mediated DA reuptake. Because DA uptake capacity depends on the turnover rate of an individual transporter and on the number of functional transporters expressed at the plasma membrane, regulation of DAT cell-surface expression is an important mechanism for fine-tuning DA neurotransmission (Beckman and Quick, 1998; Robinson, 2001; Kahlig and Galli, 2003).

Several studies have identified signal transduction pathways that modulate DAT trafficking and activity. Activation of protein kinase C (PKC), either by phorbol esters (phorbol 12-myristate 13-acetate) or by Gαs-coupled substance P receptor, decreases both DAT cell-surface expression and transport capacity (Zhang et al., 1997; Zhu et al., 1997; Daniels and Amara, 1999; Melikian and Buckley, 1999; Granas et al., 2003; Loder and Melikian, 2003). PKC-induced trafficking has been observed also for other Na+/H-exchanger-dependent neurotransmitter transporters (NTs), including the serotonin transporter and the GABA transporter GAT1 (Blakely and Bauman, 2000; Robinson, 2001). In the case of DAT, PKC down-regulation has also been observed in rat striatal synaptosomes (Vaughan et al., 1997). It is curious that PKC-induced trafficking does not seem to require phos-
phorylation of DAT itself (Granas et al., 2003) but instead requires phosphorylation of another substrate.

Tyrosine kinases, which are activated by insulin and insulin-like growth factor 1, have also been shown to regulate NT function (Law et al., 2000; Gonzalez and Robinson, 2004). Prasad et al. (1997) showed that activation of tyrosine kinases up-regulates the activity, cell-surface expression, and gene expression of the human serotonin transporter. In hippocampal neurons, short-term inhibition of tyrosine kinase down-regulates GAT1 function with a concomitant decrease in transporter cell-surface expression (Law et al., 2000). Likewise, DAT activity and cell-surface expression were also reduced by tyrosine kinase inhibitors (Doolen and Zahniser, 2001).

Insulin signaling, which enhances tyrosine kinase activity (Elmendorf and Pessin, 1999; Taha and Klip, 1999), increases norepinephrine transporter function (Apparsundaram et al., 2001) and plays a critical role in the regulation of norepinephrine uptake by angiotensin II (Yang and Raizada, 1999). The downstream effects of insulin include the activation of PI3K. This lipid kinase phosphorylates the D-3 position of phosphoinositides to generate mainly phosphatidylinositol-(3,4,5)P3 (Taha and Klip, 1999), which acts at the plasma membrane as a second messenger. Self-administration of AMPH is regulated by insulin signaling (Galici et al., 2000), and PI3K has been implicated in the regulation of the behavioral actions of psychostimulants such as AMPH and cocaine (Izzo et al., 2002).

AMPH is believed to produce its behavioral effects by increasing extracellular DA levels (Koob and Bloom, 1988). AMPH achieves this increase by competing with DA for uptake by DAT, by inducing DA efflux mediated by DAT in a Na+ - and Ca2+ -dependent manner (Khoshbouei et al., 2003; Gnegy et al., 2003), and possibly by stimulating a redistribution of DAT away from the plasma membrane (Saunders et al., 2000; Gulley et al., 2002; Chi and Reith, 2003; Kahlig and Galli, 2003). Insulin stimulation reduced AMPH-induced intracellular accumulation of DAT (Carvelli et al., 2002). This effect of insulin seems to be mediated by PI3K because transient expression of constitutively active PI3K also reduced the AMPH-induced intracellular accumulation of DAT (Carvelli et al., 2002).

Although some progress has been made in understanding how PKC affects NT localization and function (Gonzalez and Robinson, 2004), the signaling pathways involved in hormonal (e.g., insulin) regulation of NT activity and cell-surface expression are not well understood. Akt is a central player in insulin and growth factor signaling, and it is believed to regulate several cellular functions, including cell growth and apoptosis (Hanada et al., 2004). Three isoforms of Akt have been identified (Hanada et al., 2004), and each of the three Akt isoforms contain a pleckstrin homology domain that interacts with membrane lipid products of PI3K, and this interaction is required for Akt activation (Hanada et al., 2004). In mouse tissue, both Akt1 and Akt2 isoforms are ubiquitously expressed, whereas Akt3 is relatively highly expressed in brain and testis (Hanada et al., 2004). In hDAT cells, we have explored the role of endogenous Akt and recombinant Akt1 in the regulation of hDAT surface expression and in insulin regulation of hDAT cell-surface expression. We provide evidence that basal activity of Akt controls hDAT plasma membrane expression and that insulin requires the activation of Akt to regulate AMPH-induced hDAT cell-surface redistribution.

Materials and Methods

Cell Culture. A fluorescently tagged hDAT was constructed by fusing the C terminus-encoding region of the enhanced yellow fluorescent protein (YFP) cDNA from pEYFP-N1 (BD Biosciences Clontech, Palo Alto, CA) to the N terminus encoding region of the human synthetic DAT cDNA (Kahlig et al., 2004), thereby creating the fusion construct YFP-hDAT. This construct was subcloned into a bicistronic expression vector (Rees et al., 1996) to modify the expressed hDAT from a cytomegalovirus promoter and a hygromycin resistance gene from an internal ribosomal entry site (pcDNA3-Hyg), as described previously (Saunders et al., 2000). EM4 cells, a human embryonic kidney 293 cell stably expressing macropaque scavenger receptor to increase adherence (kindly provided by R. Horlick, Pharmacopeia, Cranberry, NJ), were transfected with the YFP-DAT using LipofectAMINE (Invitrogen, Carlsbad, CA), and a stably transfected pool (hDAT cells) was selected in 250 μg/ml hygromycin as described previously (Ferrari and Javitch, 1998; Saunders et al., 2000). Cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum at 37°C and 5% CO2.

Uptake of [3H]DA. [3H]DA uptake was performed as described previously (Carvelli et al., 2002). hDAT cells were seeded into 24-well plates approximately 24 h before the experiment (150,000 cells/well). After 2 h of serum starvation in KHRT buffer containing 120 mM NaCl, 4.7 mM KCl, 10 mM HEPES, 5 mM TRIZMA base, 2.2 mM CaCl2, and 10 mM dextrose with 100 μM ascorbic acid, the cells were treated in quadruplicate wells with AMPH in KHRT buffer at pH 7.4 and 37°C. The plates were removed from the incubator, and the cells were washed (three washes of 5 min each) with 4°C KHRT buffer to remove the AMPH from each well and inhibit protein trafficking (Saunders et al., 2000). The plates were then placed into an 18°C incubator in KHRT buffer containing 100 μM pargyline, a monoamine oxidase inhibitor. Fifty nanomolar concentration of [3H]DA (Amersham Biosciences, Piscataway, NJ) and 15 μM DA were added to reach a final volume of 250 μL. Cells were incubated for 2 min, and then the solution was aspirated to terminate uptake. After three quick washes with ice-cold uptake buffer, the cells were lysed with 1 ml of microscint-20 fluid (PerkinElmer Life and Analytical Sciences, Boston, MA). Radioactivity was measured in a TopCount scintillation counter (PerkinElmer). Specific uptake was defined as the total uptake minus nonspecific uptake in the presence of 10 μM mazindol. Data were analyzed with Prism 3.02 software (GraphPad Software Inc., San Diego, CA).

In the experiments in which insulin was applied, we added insulin (1:1000) to the incubating medium from a stock solution of 0.9% NaCl/12 mM HCl (vehicle) containing 1 mM insulin. The vehicle itself had no significant effect on the parameters under study (data not shown).

Cell-Surface Biotinylation. Cell-surface biotinylation experiments were performed as described previously (Saunders et al., 2000; Kahlig et al., 2004) with slight modification. hDAT cells were seeded into six-well plates (105 cells/well) approximately 24 h before the experiment. After 1 h of starvation in KHRT buffer, the cells were treated with AMPH in KHRT at 37°C for the indicated time points. The cells were washed twice with ice-cold PBS containing 0.1 mM CaCl2 and 1 mM MgCl2 (PBS-Ca-Mg) and treated with EZ-Link Sulfo-NHS-Biotin (1.5 mg/ml in PBS-Ca-Mg; Pierce Chemical, Rockford, IL) on ice for 1 h. The reaction was quenched by washing twice with 4°C PBS-Ca-Mg containing 100 mM glycine (PBS-Ca-Mg-glycine) followed by an incubation with PBS-Ca-Mg-glycine for 30 min on ice. Cells were then washed twice with 4°C PBS-Ca-Mg before lysis with 1 ml of radiimmunoprecipitation assay buffer (20 mM Tris, 20 mM EGTA, 1 mM diethiothreitol, and 1% Triton X-100) containing protease inhibitors (100 μM phenylmethylsulfonyl fluo-
ride, 5 μg/ml leupeptin, 5 μg/ml pepstatin, and 1 mM benzamidine) for 30 min on ice with constant shaking. Lysates were centrifuged at 14,000g for 30 min at 4°C. The supernatants were isolated, and biotinylated proteins were separated by incubation with ImmunoPure Immobilized Streptavidin beads (Pierce) for 1 h at room temperature with constant mixing. Beads were washed three times with radioimmunoprecipitation assay buffer containing protease inhibitors. Biotinylated proteins were then eluted with Laemmli loading buffer for 30 min at room temperature. Total cell lysates and biotinylated proteins (cell surface) were separated by SDS-polyacrylamide gel electrophoresis (7.5%) and transferred to PVDF membranes (Bio-Rad, Hercules, CA). PVDF membranes were incubated for 1.5 h in blocking buffer (5% dry milk and 0.1% Tween 20 in Tris-buffered saline) and immunoblotted with a rat monoclonal antibody directed against the N terminus of the human dopamine transporter (1:2000 in blocking buffer; Chemicon International, Temecula, CA). Immunoreactive bands were visualized using horseradish peroxidase-conjugated goat anti-rat antibody (1:5000 in blocking buffer; Santa Cruz Biotechnology Inc., Santa Cruz, CA) with ECL-Plus on hypersensitive enhanced chemiluminescence film (Amersham Biosciences). Band densities were calculated using Scion Image software (Scion Corporation, Frederick, MD) and normalized to the appropriate total extract to control for protein loading. Data were analyzed with Prism 3.02 software and reported as mean ± S.E.M.

**Transient Expression of Dominant-Negative Akt and Constitutively Active (Myristylated) Akt.** hDAT cells were transiently transfected with a “kinase dead” (KD) dominant-negative mutant (K179R) of Akt1 (Akt-KD) using the PolyFect transfection method (QIAGEN, Valencia, CA). The Akt-KD mutant was made by using polymerase chain reaction to mutate Lys179 of Akt-hemagglutinin (obtained from Dr. R. Roth, Stanford University, Stanford, CA) to an arginine, and the mutation was confirmed by DNA sequencing. Cells were incubated overnight in the presence of 2 μg of DNA per 35-mm dish (biotinylation assays) or 0.5 μg per well of a 24-well plate (uptake assays). A constitutively active Akt1 (myrAkt) (Ballou et al., 2001) subcloned into pcDNA3.1 was transfected into hDAT cells using PolyFect as described above. Immunoblot analysis demonstrated that transient expression of K179R or myrAkt did not alter protein levels of DAT with respect to cells transfected with the vector alone (data not shown). The cells were used 48 h after transfection as indicated for the uptake and biotinylation experiments.

ImmunobLOTS for phsopho-Akt and total Akt were obtained using a pS473-Akt Ab (1:500) and a carboxyl-terminal Akt mouse Ab (1:1000) (Cell Signaling Technology Inc., Beverly, MA).

**Results**

**Insulin Modulates AMPH-Induced hDAT Cell-Surface Redistribution and Dopamine Uptake.** AMPH causes hDAT to redistribute away from the plasma membrane (Saunders et al., 2000). This phenomenon is dynamin-dependent, because it is reduced by transient overexpression of K44A, a dominant-negative mutant of dynamin (Damke et al., 1994). Carvelli et al. (2002) recently demonstrated, by means of confocal imaging, that the AMPH-induced decrease in hDAT plasma membrane expression was partially restored by subsequent stimulation of the PI3K-signaling pathway with insulin. To further characterize the hormonal regulation of hDAT expression, we tested whether the timing of insulin stimulation (i.e., before/after AMPH) was important for its modulation of the AMPH-induced hDAT cell-surface redistribution. Figure 1A shows immunoblots obtained from hDAT cells treated with either vehicle (CTR), 10 μM AMPH for 30 min (AMPH 30'), or 1 μM insulin for 10 min followed by 10 μM AMPH for 30 min in the continued presence of insulin (Ins + AMPH). Although incubation of hDAT cells with AMPH significantly decreased the level of hDAT protein recovered in the surface-biotinylated fractions (Fig. 1A, trans.}

---

1. Garcia et al. 2001
2. Ballou et al. 2001
3. Damke et al. 1994
4. Carvelli et al. 2002
Expression of Constitutively Active Akt Prevents AMPH-Induced Reduction of hDAT Cell-Surface Expression and [3H]DA Uptake. Akt is a pleckstrin homology domain-containing serine/threonine kinase. Earlier reports suggested that Akt is activated upon translocation to the plasma membrane as a consequence of its binding to phosphoinositides [e.g., phosphatidylinositol-(3,4,5)P3] that are increased by stimulation of Akt with insulin (Elmendorf and Pessin, 1999; Taha and Klip, 1999). Therefore, we used a membrane-targeted constitutively active Akt (myrAkt) (Ballou et al., 2001) to probe whether Akt is part of the regulatory network required by insulin to modulate AMPH-induced trafficking of hDAT. hDAT cells were transiently transfected with either myrAkt or vector. Figure 3A shows surface biotinylation (top lane) and total (bottom lane) protein extract of transfected hDAT cells treated with either 10 μM AMPH or vehicle for 30 min. AMPH caused a decrease in the amount of hDAT proteins recovered in the biotinylated fraction of vector-transfected cell (Fig. 3A). In contrast, in the cells transfected with myrAkt, AMPH did not decrease hDAT cell-surface expression (Fig. 3A). Figure 3B shows quantification of the biotinylated bands obtained from three different experiments. In vector (□) and myrAkt (■)-transfected cells, AMPH decreased hDAT cell-surface expression to 74 ± 7.2% and 98 ± 1.7% of control conditions, respectively (Fig. 3B). Overexpression of myrAkt did not, however, alter basal levels of hDAT plasma membrane expression (data not shown).
Consistent with these effects on cell-surface expression, in hDAT cells transfected with the empty vector, AMPH reduced \(^{[3]}\text{H}\)DA uptake to 72 ± 7% of control (Fig. 3C, □). In contrast, expression of myrAkt (Fig. 3C, ■) blocked the ability of AMPH to reduce \(^{[3]}\text{H}\)DA uptake. Also consistent with the effects on cell-surface expression, myrAkt transfection did not significantly alter \(^{[3]}\text{H}\)DA uptake with respect to vector control (Fig. 3C).

**Overexpression of a Dominant-Negative Mutant of Akt Impairs Surface Expression of hDAT and Insulin Modulation of AMPH-Induced hDAT Cell-Surface Redistribution.** AMPH application decreased both hDAT expression at the plasma membrane and phosphorylation of Akt on Ser473 (Figs. 1 and 2), suggesting that basal activity of Akt is necessary to maintain normal surface levels of DAT. Therefore, we tested the effects of an Akt inhibitor, ML9 (Smith et al., 2000; Fiory et al., 2004), originally characterized as a competitive inhibitor of a low myosin-light chain kinase (Saitoh et al., 1987) on cell-surface expression of hDAT. Incubation of hDAT cells with 100 \(\mu\text{M}\) ML9 for 30 min produced a significant decrease in the level of hDAT protein recovered in the biotinylated fraction (Fig. 4A). Figure 4B shows quantification of the biotinylated bands obtained from six different experiments. In ML9-treated cells (ML9, ■), the biotinylated fraction was 72 ± 6.6% of vehicle control (CTR, □). Consistent with these effects on surface expression, incubation of hDAT cells with 100 \(\mu\text{M}\) ML9 for different time periods (between 5 and 60 min) resulted in a time-dependent decrease in \(^{[3]}\text{H}\)DA uptake (Fig. 4C). ML9 decreased \(^{[3]}\text{H}\)DA uptake to 74.6 ± 6.1% of control conditions after 5 min of drug application.

To assess whether insulin modulation of the AMPH-induced hDAT cell-surface redistribution requires Akt activation, 48 h after transfection with Akt-KD or vector, hDAT cells were treated with either 10 \(\mu\text{M}\) AMPH for 40 min or 1 \(\mu\text{M}\) insulin for 10 min followed by 10 \(\mu\text{M}\) AMPH for 30 min in the continued presence of insulin (Fig. 5). Figure 5A shows that upon insulin stimulation, the amount of hDAT recovered in the biotinylated fraction is reduced in hDAT cells overexpressing Akt-KD with respect to vector transfection. Figure 5B shows quantification of the biotinylated bands obtained from four different experiments. Data were normalized to total protein and were expressed as a percentage of vector-transfected hDAT cells treated with AMPH. Insulin significantly increased hDAT cell-surface expression in vector-transfected cells after AMPH treatment (120 ± 17% with respect to AMPH treatment alone; □). On the other hand, transfection of Akt-KD blocked the insulin-mediated increase in hDAT plasma membrane expression after AMPH treatment (■). The amount of hDAT recovered in the biotinylated fraction was not affected by transfecting hDAT cells with vector (Fig. 5C, top lane, left; compare Vector versus CTR). In vector-transfected cells, plasma-membrane hDAT was 107 ± 3% of control condition (n = 3, p > 0.05 by two-tailed t test). In contrast, overexpression of Akt-KD in hDAT cells decreased cell-surface expression of hDAT (Fig. 5C, top lane, right; compare Akt-KD versus vector). As in ML9- and AMPH-treated cells (Figs. 1 and 4), in Akt-KD–transfected cells, the amount of hDAT recovered in the biotinylated fraction was 61 ± 10% of vector control condition, suggesting that basal Akt activity regulates hDAT cell-surface expression (n = 3; level of significance equal to p < 0.05 by two-tailed t test).

ML9 also reduced the ability of insulin to modulate AMPH-induced hDAT cell-surface redistribution. Figure 6A shows an immunoblot of biotinylated and total hDAT protein frac-
Akt is involved in multiple cellular functions, including growth, apoptosis (Hanada et al., 2004), and glucose metabolism (George et al., 2004). Our data demonstrate that Akt plays an essential role in the homeostatic regulation of hDAT activity. A pharmacological inhibitor of Akt, ML9, decreased hDAT surface expression and DA uptake in a time-dependent manner.
fashion (Fig. 4). Similar results were obtained with a dominant-negative mutant of Akt (Fig. 5C). These results, for the first time, suggest that basal Akt activity maintains basal cell-surface DAT levels and thereby basal levels of DA uptake.

It is not yet known whether Akt activity regulates hDAT cell-surface expression, and consequently DA uptake, by controlling the rate of DAT endocytosis and/or its rate of ectodomain shedding. It is known, however, that in adipocytes and muscles, insulin induces the translocation of the intracellular GLUT4 glucose transporter to the plasma membrane (Cheatham and Kahn, 1995) and that this translocation is mediated by Akt (Elmendorf and Pessin, 1999). Therefore, we explored whether the insulin modulation of the AMPH-induced decrease in hDAT plasma-membrane expression (Fig. 1) requires activation of Akt. The insulin modulation of AMPH-induced cell-surface redistribution was blocked by overexpression of a dominant mutant of Akt (Fig. 5) and by preincubation with the Akt inhibitor ML9 (Fig. 6). Because AMPH inhibits Akt activity (Fig. 2), these data suggest that insulin requires activation of Akt to restore normal hDAT plasma-membrane expression upon AMPH treatment. Moreover, increasing Akt activity by overexpressing the constitutively active myrAkt blocked AMPH-induced hDAT cell-surface redistribution (Fig. 3B) as well as the ability of AMPH to decrease DA uptake (Fig. 3C), suggesting a direct correlation between insulin modulation of AMPH-induced hDAT cell-surface redistribution and Akt activity.

A well-characterized signaling event elicited by insulin is the regulation of glucose homeostasis. In nonbrain tissue such as skeletal muscle and adipose tissue, insulin signaling stimulates an increase of glucose reuptake (Taha and Klip, 1999). Although insulin crosses the blood-brain barrier (Banks and Kastin, 1998), neurons use insulin-independent mechanisms to obtain glucose. Therefore, it is conceivable that insulin in the central nervous system could modulate cellular processes distinct from those involved in the cellular supply and metabolism of glucose. Indeed, Patterson and coworkers (1998) have shown that insulin regulates dopaminergic neurotransmission, although the underlying mechanism remains unclear. DA uptake in striatal preparations from fasted hypoinsulinemic rats was significantly decreased compared with control rats (Patterson et al., 1998). The reduction in DA uptake resulted from a decrease in transporter $V_{\text{max}}$ and not from a change in the $K_{\text{m}}$ value for DA. Such a reduction in $V_{\text{max}}$ is consistent with an increased intracellular accumulation of DAT in these diabetic, insulin-deficient animals. Consistent with this hypothesis and with our data, the $V_{\text{max}}$ of DA uptake was restored to control levels after incubation of striatal suspensions from fasted animals with 1 nM insulin for 30 min (Patterson et al., 1998). These data strongly suggest that changes in insulin levels in the limbic area of the brain could affect DA uptake and, consequently, extracellular DA levels. It is noteworthy that no changes in DA uptake were observed in the nucleus accumbens of food-deprived rats, suggesting that insulin selectively affects brain regions.

AMPH is believed to increase extracellular DA levels both by competing with DA for DAT and through facilitated exchange (Fischer and Cho, 1979). In addition, AMPH has been shown to decrease DAT cell-surface expression and DA uptake, which also probably contributes to an increase in extracellular DA levels (Saunders et al., 2000; Gulley et al., 2002; Little et al., 2002; Chi and Reith, 2003). It is interesting that in pharmacologically induced diabetic rats (i.e., alloxan-treated), the ability of short-term administration of AMPH to induce anorexia, stereotyped behavior, and increased locomotor activity was markedly attenuated, whereas subsequent administration of insulin reversed this attenuation (Marshall, 1978). Likewise, Galici et al. (2003) demonstrated that in diabetic rats, AMPH self-administration and DA uptake in striatum were both reduced. Together, these studies suggest that insulin pathways in the brain may play an important role in regulating DAT activity, extracellular DA levels, and the actions of AMPH.

Regulation of hDAT cell-surface expression may represent an important mechanism through which insulin signaling modulates the dopaminergic system and the actions of AMPH. In this study, we demonstrated that insulin offsets the ability of AMPH to decrease hDAT plasma membrane expression and DA uptake. This insulin effect did not depend on the time at which insulin was applied (i.e., before or after AMPH incubation), indicating that the AMPH-induced decrease in DA uptake is a consequence of hDAT cell-surface redistribution rather than hDAT inactivation (Figs. 1 and 2).

Several studies have implicated PI3K in the regulation of trafficking and activity of the glucose and glutamate transporters (Clarke et al., 1994; James and Piper, 1994; Davis et al., 1998). Likewise, PI3K has been shown to be essential for insulin modulation of hDAT function in striatal synaptosomes and hDAT cells (Carvelli et al., 2002). PI3K inhibitors, such as LY294002, blocked the insulin-induced increase in DA uptake (Carvelli et al., 2002). Moreover, in hDAT cells, overexpression of a constitutively active mutant of PI3K increased DA uptake (Carvelli et al., 2002). These data suggested that insulin signaling, in general and PI3K in particular regulate DA uptake, and we have now shown that Akt activation seems to be essential for the effect of insulin on hDAT. It is interesting that although both insulin and exogenous PI3K increased basal levels of DA uptake in hDAT cells (Carvelli et al., 2002), overexpression of...
constitutively active Akt did not (Fig. 3C). Thus, in addition to its effects on Akt, insulin (and probably PI3K) might also regulate DAT activity through another mechanism, although the myrAkt may not be sufficiently constitutively active to mimic the effects of insulin on Akt activation; therefore, Akt may be the only mechanism by which insulin affects DAT cell-surface expression.

In summary, our results demonstrate that the basal activity of Akt is essential for maintaining cell-surface expression of hDAT and that insulin modulation of AMPH-induced trafficking of hDAT requires Akt activation. Our results could provide a mechanism for hormonal regulation of drug abuse and suggest that the insulin signaling pathway, including Akt, may represent a new cellular target for substance-abuse therapies.

References
Banks WA and Rastin AJ (1998) Differential permeability of the blood-brain barrier represent a new cellular target for substance-abuse therapies. A mechanism for hormonal regulation of drug abuse and sug- esting of hDAT requires Akt activation. Our results could provide a mechanism for hormonal regulation of drug abuse and suggest that the insulin signaling pathway, including Akt, may represent a new cellular target for substance-abuse therapies.

References
Banks WA and Rastin AJ (1998) Differential permeability of the blood-brain barrier represent a new cellular target for substance-abuse therapies. A mechanism for hormonal regulation of drug abuse and suggesting of hDAT requires Akt activation. Our results could provide a mechanism for hormonal regulation of drug abuse and suggest that the insulin signaling pathway, including Akt, may represent a new cellular target for substance-abuse therapies.

References
Banks WA and Rastin AJ (1998) Differential permeability of the blood-brain barrier represent a new cellular target for substance-abuse therapies. A mechanism for hormonal regulation of drug abuse and suggesting of hDAT requires Akt activation. Our results could provide a mechanism for hormonal regulation of drug abuse and suggest that the insulin signaling pathway, including Akt, may represent a new cellular target for substance-abuse therapies.

References
Banks WA and Rastin AJ (1998) Differential permeability of the blood-brain barrier represent a new cellular target for substance-abuse therapies. A mechanism for hormonal regulation of drug abuse and suggesting of hDAT requires Akt activation. Our results could provide a mechanism for hormonal regulation of drug abuse and suggest that the insulin signaling pathway, including Akt, may represent a new cellular target for substance-abuse therapies.

References
Banks WA and Rastin AJ (1998) Differential permeability of the blood-brain barrier represent a new cellular target for substance-abuse therapies. A mechanism for hormonal regulation of drug abuse and suggesting of hDAT requires Akt activation. Our results could provide a mechanism for hormonal regulation of drug abuse and suggest that the insulin signaling pathway, including Akt, may represent a new cellular target for substance-abuse therapies.

References
Banks WA and Rastin AJ (1998) Differential permeability of the blood-brain barrier represent a new cellular target for substance-abuse therapies. A mechanism for hormonal regulation of drug abuse and suggesting of hDAT requires Akt activation. Our results could provide a mechanism for hormonal regulation of drug abuse and suggest that the insulin signaling pathway, including Akt, may represent a new cellular target for substance-abuse therapies.

References
Banks WA and Rastin AJ (1998) Differential permeability of the blood-brain barrier represent a new cellular target for substance-abuse therapies. A mechanism for hormonal regulation of drug abuse and suggesting of hDAT requires Akt activation. Our results could provide a mechanism for hormonal regulation of drug abuse and suggest that the insulin signaling pathway, including Akt, may represent a new cellular target for substance-abuse therapies.

References
Banks WA and Rastin AJ (1998) Differential permeability of the blood-brain barrier represent a new cellular target for substance-abuse therapies. A mechanism for hormonal regulation of drug abuse and suggesting of hDAT requires Akt activation. Our results could provide a mechanism for hormonal regulation of drug abuse and suggest that the insulin signaling pathway, including Akt, may represent a new cellular target for substance-abuse therapies.

References
Banks WA and Rastin AJ (1998) Differential permeability of the blood-brain barrier represent a new cellular target for substance-abuse therapies. A mechanism for hormonal regulation of drug abuse and suggesting of hDAT requires Akt activation. Our results could provide a mechanism for hormonal regulation of drug abuse and suggest that the insulin signaling pathway, including Akt, may represent a new cellular target for substance-abuse therapies.

References
Banks WA and Rastin AJ (1998) Differential permeability of the blood-brain barrier represent a new cellular target for substance-abuse therapies. A mechanism for hormonal regulation of drug abuse and suggesting of hDAT requires Akt activation. Our results could provide a mechanism for hormonal regulation of drug abuse and suggest that the insulin signaling pathway, including Akt, may represent a new cellular target for substance-abuse therapies.

References
Banks WA and Rastin AJ (1998) Differential permeability of the blood-brain barrier represent a new cellular target for substance-abuse therapies. A mechanism for hormonal regulation of drug abuse and suggesting of hDAT requires Akt activation. Our results could provide a mechanism for hormonal regulation of drug abuse and suggest that the insulin signaling pathway, including Akt, may represent a new cellular target for substance-abuse therapies.